AAP
TGTX icon

Arax Advisory Partners’s TG Therapeutics TGTX Stock Holding History

Arax Advisory Partners’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$73.8K Buy
1,344
+1,258
+1,463% +$51.5K ﹤0.01% 2963
2026
Q1 		$2.86K Sell
86
-49
-36% -$1.46K ﹤0.01% 2997
2025
Q4 		$4.03K Buy
+135
New +$4.41K ﹤0.01% 2966
2025
Q1 		– Sell
-20
Closed -$602 – 3033
2024
Q4 		$602 Buy
+20
New +$574 ﹤0.01% 2297

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Arax Advisory Partners's TGTX Position: Q2 2026 in Review

Arax Advisory Partners increased its TG Therapeutics (TGTX) stake by 1,463% in Q2 2026, buying an estimated $51.5K and bringing the position to 1,344 shares worth $73.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2963.

Arax Advisory Partners first reported a position in TGTX in Q4 2024 and has held it in 4 quarters since. 431 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Arax Advisory Partners held 1,344 shares of TG Therapeutics worth $73.8K as of Q2 2026.
  • Arax Advisory Partners bought 1,258 TG Therapeutics shares in Q2 2026, an estimated $51.5K.
  • TG Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #2963 holding.
  • Arax Advisory Partners first reported a position in TG Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • 431 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.